David Humes

H. David Humes, M.D., graduated from the medical school of the University of California, San Francisco, and joined the faculties of Harvard Medical School and the University of Michigan and is a board certified Nephrologist on staff at the University of Michigan.  He has chaired the University of Michigan’s Department of Internal Medicine and presently holds the rank of Professor.  He is an international authority in the areas of acute renal failure, stem cell biology,  tissue engineering, and cell therapy devices.  His laboratory has received international attention for its work in the development of the bioartificial kidney and immune cell therapy.  Dr. Humes is active in the for-profit sector.  Most notably, he has pioneered cell therapy devices to treat acute and organ failures

• Scientific founder of IBT as well as Nephros Therapeutics, CytoPherx, and SeaStar Medical, biotechnology companies directed toward various devices to treat acute organ failure
• Has 70 patents issued or pending. 
• Published over 250 scientific articles and book chapters and was editor-in-chief of Kelley’s Textbook of Internal Medicine. 
• Elected to numerous prestigious honorary scientific societies, and has earned several highly acclaimed awards in Nephrology, including: The Kolff Prize, The President’s Award from the National Kidney Foundation, and the A.N. Richards Distinguished Achievement Award in Nephrology.